Medtronic (NYSE:MDT) versus Green Thumb Industries (OTCMKTS:GTBIF) Head to Head Analysis

Green Thumb Industries (OTCMKTS:GTBIF) and Medtronic (NYSE:MDT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.

Institutional and Insider Ownership

0.1% of Green Thumb Industries shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 9.4% of Green Thumb Industries shares are held by insiders. Comparatively, 0.3% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Green Thumb Industries and Medtronic”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Green Thumb Industries	$1.18 billion	1.16	$114.15 million	$0.48	13.65
Medtronic	$33.54 billion	3.33	$4.66 billion	$3.59	24.25

Medtronic has higher revenue and earnings than Green Thumb Industries. Green Thumb Industries is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Green Thumb Industries and Medtronic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Green Thumb Industries	9.71%	5.47%	3.81%
Medtronic	13.00%	14.82%	7.88%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Green Thumb Industries and Medtronic, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Green Thumb Industries	0	1	1	1	3.00
Medtronic	0	10	15	1	2.65

Medtronic has a consensus target price of $110.74, suggesting a potential upside of 27.20%. Given Medtronic’s higher probable upside, analysts clearly believe Medtronic is more favorable than Green Thumb Industries.

Volatility & Risk

Green Thumb Industries has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.

Summary

Medtronic beats Green Thumb Industries on 11 of the 14 factors compared between the two stocks.

About Green Thumb Industries

Green Thumb Industries Inc. manufactures, distributes, markets, and sells of cannabis products for medical and adult-use in the United States. It operates through two segments, Retail and Consumer Packaged Goods. The company offers cannabis flower; processed and packaged products, including pre-rolls, concentrates, vapes, capsules, tinctures, edibles, topicals, and other cannabis-related products under the &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RHYTHM brands. It distributes its products primarily to third-party retail customers and sells finished products directly to consumers in its own retail stores, as well as direct-to consumer delivery channel. Green Thumb Industries Inc. was founded in 2014 and is headquartered in Chicago, Illinois.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.